Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Buy” by Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus rating of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $22.50.

A number of research analysts recently weighed in on IMNM shares. Guggenheim reiterated a “buy” rating and issued a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. Wedbush reiterated an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a research note on Thursday, August 7th. Evercore ISI started coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Immunome Trading Down 3.9%

Immunome stock opened at $9.51 on Tuesday. Immunome has a 1-year low of $5.15 and a 1-year high of $16.73. The firm has a market capitalization of $827.75 million, a price-to-earnings ratio of -3.09 and a beta of 1.92. The firm has a 50 day simple moving average of $9.79 and a 200 day simple moving average of $8.84.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. On average, equities research analysts forecast that Immunome will post -2.21 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Immunome by 2,822.9% during the 1st quarter. GAMMA Investing LLC now owns 6,138 shares of the company’s stock valued at $410,000 after purchasing an additional 5,928 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Immunome during the 4th quarter valued at $95,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.